Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Aug 25, 6:06PM CDT

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat...

SCYX : 5.19 (-1.33%)
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Aug 25, 6:06PM CDT

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat...

SCYX : 5.19 (-1.33%)
Scynexis: Q2 Earnings Snapshot AP - Mon Aug 10, 3:56PM CDT

Scynexis: Q2 Earnings Snapshot

SCYX : 5.19 (-1.33%)
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire - Mon Aug 10, 3:30PM CDT

Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the...

SCYX : 5.19 (-1.33%)
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) GlobeNewswire - Tue Jun 30, 7:00AM CDT

JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation...

SCYX : 5.19 (-1.33%)
SCYNEXIS Announces One-for-Eight Reverse Stock Split GlobeNewswire - Fri May 22, 3:15PM CDT

JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare...

SCYX : 5.19 (-1.33%)
Scynexis: Q1 Earnings Snapshot AP - Mon May 11, 3:43PM CDT

Scynexis: Q1 Earnings Snapshot

SCYX : 5.19 (-1.33%)
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire - Mon May 11, 3:23PM CDT

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD) A Phase...

SCYX : 5.19 (-1.33%)
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed May 6, 8:15PM CDT

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address...

SCYX : 5.19 (-1.33%)
SCYNEXIS Announces $40.0 Million Private Placement GlobeNewswire - Tue Mar 31, 5:45AM CDT

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies...

SCYX : 5.19 (-1.33%)

Barchart Exclusives

Dividend Aristocrat or Dividend Cuts: How to Evaluate the NKE Stock Payout as the Nike Turnaround Drags On Barchart - Tue Aug 25, 6:30PM CDT
Nike is on the verge of becoming a dividend aristocrat. However, its earnings need to improve materially, or else the payouts would become increasingly unsustainable. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.